Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics (Nasdaq: ABEO) granted equity awards to new non-executive employees under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Abeona Therapeutics (Nasdaq: ABEO) granted equity awards to new non-executive employees under Nasdaq Listing Rule 5635(c)(4). On May 31, 2026, the Compensation Committee approved restricted stock awards covering up to 13,800 shares, vesting in three equal annual installments over three years, subject to continued employment.

Argus Jun 1 session

-2.60% close to close Open Argus

Details

News Market Reaction – ABEO

In the Jun 1 session, ABEO declined 2.60%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine equity inducement grants totaling 13,800 restricted shares for sev...

Analysis

This announcement details routine equity inducement grants totaling 13,800 restricted shares for seven new non-executive employees under Nasdaq Listing Rule 5635(c)(4), vesting over three years. Contextually, Abeona recently reported its first meaningful ZEVASKYN revenue of $8.7 million and held $168.3 million in cash and short-term investments. Investors may monitor the cumulative scale of such grants versus prior awards, like the 112,621 shares granted in April, alongside progress in commercialization and pipeline execution.

Key Figures

New inducement hires: 7 individuals New inducement shares: 13,800 restricted shares Vesting schedule: One-third per year over 3 years +5 more

New inducement hires

7 individuals

New non-executive employees receiving inducement equity awards

New inducement shares

13,800 restricted shares

Aggregate restricted stock awards granted May 31, 2026

Vesting schedule

One-third per year over 3 years

Time-based vesting of new inducement restricted stock

Prior inducement shares

112,621 restricted shares

Inducement awards granted April 30, 2026

Q1 2026 product revenue

$8.7 million

First commercial quarter for ZEVASKYN

Cash and equivalents

$61.4 million

As of March 31, 2026 (10-Q)

Short-term investments

$106.9 million

As of March 31, 2026 (10-Q)

Market capitalization

$329,431,932

Pre-news market value based on latest price

Historical Context

5 past events · Latest: May 26

5 events

1. May 26

   Investor conferences

   24h Move

   +0.9%

   Announced participation in two June 2026 healthcare investor conferences.

2. May 13

   Earnings and update

   24h Move

   +0.5%

   Reported first commercial ZEVASKYN revenue and provided pipeline and cash update.

3. May 11

   Treatment center expansion

   24h Move

   -0.7%

   Activated CHOP as sixth Qualified Treatment Center for ZEVASKYN.

4. May 04

   Earnings date set

   24h Move

   +9.6%

   Announced date and access details for Q1 2026 earnings call.

5. May 01

   Inducement grants

   24h Move

   -0.6%

   Granted up to 112,621 restricted shares as inducement awards to new hires.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), restricted stock, restricted shares

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock financial

"granted restricted stock equity awards as a material inducement to employment"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

restricted shares financial

"awards relate to, in the aggregate, up to 13,800 restricted shares of Abeona common stock."

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CLEVELAND, June 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

On May 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to seven individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 13,800 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the grant date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.

About Abeona Therapeutics

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN^® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com.

ZEVASKYN^®, Abeona Assist™, Abeona Therapeutics^®, and their related logos are trademarks of Abeona Therapeutics Inc.

Contacts:

Investor and Media
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com

Investor
Lee M. Stern
Meru Advisors
lstern@meruadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What employee inducement grants did Abeona Therapeutics (ABEO) announce on June 1, 2026?

Abeona Therapeutics announced restricted stock inducement grants for seven new non-executive employees. According to Abeona, these awards cover up to 13,800 shares of common stock and are intended as a material inducement for their employment with the company.

How many Abeona Therapeutics (ABEO) shares are included in the 2026 inducement equity awards?

The inducement equity awards relate to an aggregate of up to 13,800 restricted shares of Abeona common stock. According to Abeona, these shares are allocated across seven newly hired non-executive employees as part of their employment compensation packages.

What is the vesting schedule for Abeona Therapeutics (ABEO) 2026 inducement restricted stock awards?

The restricted stock awards vest over three years in equal annual installments. According to Abeona, one-third of the shares vests on each anniversary of the May 31, 2026 grant date, contingent on the employee’s continued employment at each vesting date.

Why did Abeona Therapeutics (ABEO) grant equity awards under Nasdaq Listing Rule 5635(c)(4)?

Abeona used Nasdaq Listing Rule 5635(c)(4) to grant equity as a material inducement to new hires. According to Abeona, this framework allows non-plan grants to seven new non-executive employees as part of their overall employment packages.

Who received Abeona Therapeutics (ABEO) inducement grants announced in June 2026?

Seven newly hired non-executive employees received the inducement restricted stock grants. According to Abeona, these individuals joined the company and were granted equity awards as a material inducement to employment, subject to a three-year time-based vesting schedule.